PERRY MICHAEL S
SEC CIK 1250379 · EDGAR
BoughtSold
Most active insiders at ARWR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Anzalone Christopher Richard | CEO, Dir | — | $24.01M |
| 2 | Hamilton James C | Chief Medical Off | — | $4.63M |
| 3 | O'Brien Patrick | COO | — | $3.12M |
| 4 | PERRY MICHAEL S | Dir | — | $2.00M |
| 5 | Ferrari Mauro | Dir | — | $1.02M |
| 6 | Apel Daniel Joseph | CFO | — | $934.3K |
| 7 | OLUKOTUN ADEOYE Y | Dir | — | $850.5K |
| 8 | Vakiener Victoria | Dir | — | $679.5K |
| 9 | Waddill William D. | Dir | — | $566.0K |
| 10 | Lu Hongbo | Dir | — | $228.3K |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-20 17:22 | 2026-08-18 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | S - Sale | $87.30 | -11.6K | 111.5K | -9% | -$1.01M | |
| 2025-12-18 | 2025-12-16 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +7,819 | 123.1K | +7% | $0 | |
| 2025-12-09 | 2025-12-05 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | S - Sale | $61.03 | -16.2K | 115.2K | -12% | -$991.7K | |
| 2024-12-20 | 2024-12-18 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | A - Grant | $22.99 | +16.7K | 131.5K | +15% | +$384.7K | |
| 2023-12-19 | 2023-12-15 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | A - Grant | $25.41 | +15.0K | 114.8K | +15% | +$380.8K | |
| D | 2023-01-11 | 2023-01-10 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +7,867 | 99.8K | +9% | $0 |
| D | 2022-11-22 | 2022-11-21 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | Dir | S - Sale+OE | $7.18 | -150.0K | 229.5K | -40% | -$1.08M |
| D | 2022-11-22 | 2022-11-21 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | Dir | M - OptEx | $5.99 | +150.0K | 379.5K | +65% | +$898.5K |
| D | 2022-09-06 | 2022-09-01 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | A - Grant | $0.00 | +2,980 | 301.0K | +1.0% | $0 |
| 2022-06-02 | 2022-06-01 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | J - Other | $0.00 | -23.8K | 298.0K | -7% | $0 | |
| D | 2022-02-25 | 2022-02-24 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | S - Sale | $8.74 | -10.8K | 321.7K | -3% | -$94.5K |
| DM | 2022-02-25 | 2022-02-23 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | A - Grant | $0.00 | +29.7K | 332.5K | +10% | $0 |
| 2022-01-07 | 2022-01-07 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | A - Grant | $0.00 | +6,400 | 91.9K | +7% | $0 | |
| M | 2022-01-04 | 2022-01-03 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | PERRY MICHAEL S | Dir | S - Sale | $64.71 | -4,500 | 87.4K | -5% | -$291.2K |
| DM | 2021-12-27 | 2021-12-22 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | A - Grant | — | +71.4K | 279.0K | +34% | — |
| 2021-09-07 | 2021-09-01 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | S - Sale | $20.68 | -11.2K | 237.6K | -5% | -$232.0K | |
| 2021-09-07 | 2021-09-01 | RCEL | AVITA Medical, Inc. | PERRY MICHAEL S | CEO, Dir | A - Grant | $0.00 | +23.8K | 248.9K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations